GlassScriptPhysician profile
Miranda Micucci
NPI 1437882537
$1,451.29
in general payments reported to CMS, 2019-2025
25 companies · $602 in 2025
The $602 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $34.16 · 2023: $317 · 2024: $498 · 2025: $602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,382 · Entertainment: $35.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,381.97 |
| Entertainment | $35.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $204.57 | 2023-2025 | |
| Novo Nordisk INC | $203.22 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $164.04 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $133.96 | 2023-2025 | |
| Lilly USA, LLC | $92.00 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.07 | 2023-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $60.70 | 2024-2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Amgen INC. | $52.13 | 2024-2025 | Evenity, Prolia, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $52.12 | 2024-2025 | |
| Philips North America LLC | $38.35 | 2024-2025 | Extended Holter, (5050) Extended Holter |
| Optos, INC. | $35.16 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Boston Scientific Corporation | $34.45 | 2024 | Watchman Flx |
| Phathom Pharmaceuticals, INC. | $29.42 | 2024-2025 | Voquezna |
| Actelion Pharmaceuticals US, INC. | $29.19 | 2025 | Opsumit, Uptravi |
| Takeda Pharmaceuticals U.S.A., INC. | $29.14 | 2024-2025 | Trintellix |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $25.77 | 2025 | Rexulti |
| Dexcom, INC. | $23.35 | 2024 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $22.79 | 2024 | Nexletol |
| Sanofi Pasteur INC. | $22.40 | 2023 | |
| Redhill Biopharma INC. | $21.84 | 2023 | Movantik, Talicia, Aemcolo |
| Medtronic, INC. | $20.38 | 2025 | Inceptiv |
| Exact Sciences Corporation | $19.35 | 2025 | The Cologuard Plus Collection Kit |
| Lundbeck LLC | $18.24 | 2023 | Vyepti |
| Glaxosmithkline, LLC. | $17.68 | 2025 | Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $16.97 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miranda Micucci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.